The global Respiratory Disease Testing market size accounted for USD 3.0 Billion in 2020 and is expected to reach USD 4.2 Billion by 2028, growing at a CAGR of around 3.8% between 2021 and 2028.
The global Respiratory Disease Testing market accounted for USD 3.0 Billion in 2020 and is expected to reach USD 4.2 Billion by 2028, growing at a CAGR of around 3.8% between 2021 and 2028.
The respiratory system is one of the vital systems of the human body. The respiratory system plays an important role in breathing. Breathing is usually habitual and is controlled automatically by the respiratory center at the base of the brain. In addition, the respiratory system also helps to stabilize blood-alkaline balance (pH), remove toxic waste and regulate temperature. Respiratory diseases inhibit this usual operation of the respiratory system and are usually caused as a result of the inhalation of dangerous agents, smoking, and unhealthy lifestyles.
The global Respiratory Disease Testing market has witnessed growth during the pandemic. This is mainly attributed to the fact that the COVID-19 pandemic situation has led to a rise in demand for public health surveillance and clinical care. However, the rising difficulty in healthcare delivery has slightly challenged the market in 2020.
However, the market would remain bullish in the upcoming year. The growth of the global Respiratory Disease Testing market size is estimated on the basis of the COVID-19 outbreak. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.
Respiratory tests such as spirometry, lung volume, peak flow test, imaging, blood gas test, and a few other tests are used to diagnose respiratory disease. Equipment used to detect pulmonary abnormalities hold immense potential due to the increasing prevalence of various respiratory diseases Moreover, technological advancements and a growing aged population would drive the global respiratory disease testing market. However, portable spirometers and the low adoption rate of digital radiography may curb the growth of the respiratory disease testing market during the forecast period. However, the budding market in Asia-Pacific can act as a potential opportunity for the respiratory disease testing market during the forecast period.
Based on the type of the test, the global respiratory disease testing market has been segmented into imaging tests, peak flow tests, blood gas tests, spirometry, lung volume test, and other tests. The imaging test segment holds the largest share of the global respiratory disease testing market. The global respiratory disease testing market is segmented into three major end-user segments i.e. physician offices, hospitals, and clinical laboratories. Hospitals hold the largest market share of the respiratory disease testing market in 2020.
North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa are key regional segments of the global respiratory disease testing market. North America holds the largest market share for respiratory disease testing in 2020. The dominance of the region was primarily due to the rising popularity of portable devices, increasing the prevalence of respiratory diseases, and growing demand for home health care devices and services. The respiratory disease testing market in Asia-Pacific is expected to grow at the fastest growth rate during the forecast period. Latin America is projected to expand at a noticeable growth rate during the forecast period.
Request Free Sample
Request Free Sample
Some of the major players in the global Respiratory Disease Testing market include Medical Technologies, Inc., Carestream Health, Inc., SDI Diagnostics, Nihon Kohden Corporation, CareFusion Corporation, Smiths Medical, COSMED, Perkin Elmer, Inc., Philips Healthcare, MGC Diagnostic Corporation, Futuremed America, Inc. and GE Healthcare among others.
By Products
By End-user
By Region
FrequentlyAsked Questions
The global Respiratory Disease Testing Market was valued at USD 3.0 Billion in 2020.
The global Respiratory Disease Testing Market is expected to reach USD 4.2 Billion by 2028, growing at a CAGR of 3.8% between 2021 to 2028.
Some of the key factors driving the global Respiratory Disease Testing Market growth are increasing prevalence of various respiratory diseases and growing aged population.
North America is expected to remain the dominant region over the forecast period. North America followed by Asia-Pacific and Europe in terms of demand for Respiratory Disease Testing.
Some of the major players of global Respiratory Disease Testing market Medical Technologies, Inc., Carestream Health, Inc., SDI Diagnostics, Nihon Kohden Corporation, CareFusion Corporation, Smiths Medical, COSMED, Perkin Elmer, Inc., Philips Healthcare, MGC Diagnostic Corporation, Futuremed America, Inc. and GE Healthcare among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed